416 related articles for article (PubMed ID: 32683833)
1. [A prognostic nomogram for metastasized colorectal cancer patients treated with cetuximab].
Zhong LP; Li D; Zhu LZ; Fang XF; Xiao Q; Ding KF; Yuan Y
Zhonghua Wei Chang Wai Ke Za Zhi; 2020 Jul; 23(7):701-708. PubMed ID: 32683833
[No Abstract] [Full Text] [Related]
2. Prognostic Nomogram and Patterns of Use of FOLFIRI-Aflibercept in Advanced Colorectal Cancer: A Real-World Data Analysis.
Fernández Montes A; López López C; Argilés Martínez G; Páez López D; López Muñoz AM; García Paredes B; Gutiérrez Abad D; Castañón López C; Jiménez Fonseca P; Gallego Plazas J; López Doldán MC; Martínez de Castro E; Sánchez Cánovas M; Tobeña Puyal M; Llorente Ayala B; Juez Martel I; López Flores M; Carmona-Bayonas A
Oncologist; 2019 Aug; 24(8):e687-e695. PubMed ID: 31147489
[TBL] [Abstract][Full Text] [Related]
3. Continuation of Bevacizumab vs Cetuximab Plus Chemotherapy After First Progression in KRAS Wild-Type Metastatic Colorectal Cancer: The UNICANCER PRODIGE18 Randomized Clinical Trial.
Bennouna J; Hiret S; Bertaut A; Bouché O; Deplanque G; Borel C; François E; Conroy T; Ghiringhelli F; des Guetz G; Seitz JF; Artru P; Hebbar M; Stanbury T; Denis MG; Adenis A; Borg C
JAMA Oncol; 2019 Jan; 5(1):83-90. PubMed ID: 30422156
[TBL] [Abstract][Full Text] [Related]
4. FOLFIRI and Cetuximab Every Second Week for First-Line Treatment of KRAS Wild-Type Metastatic Colorectal Cancer According to Phosphatase and Tensin Homolog Expression: A Phase II Study.
Personeni N; Rimassa L; Verusio C; Barni S; Rubino L; Bozzarelli S; Villa E; Carnaghi C; Tronconi MC; Gerardi C; Galli F; Floriani I; Destro A; Raschioni C; Labianca R; Santoro A
Clin Colorectal Cancer; 2015 Sep; 14(3):162-9. PubMed ID: 25861836
[TBL] [Abstract][Full Text] [Related]
5. Rechallenge for Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer With Acquired Resistance to First-line Cetuximab and Irinotecan: A Phase 2 Single-Arm Clinical Trial.
Cremolini C; Rossini D; Dell'Aquila E; Lonardi S; Conca E; Del Re M; Busico A; Pietrantonio F; Danesi R; Aprile G; Tamburini E; Barone C; Masi G; Pantano F; Pucci F; Corsi DC; Pella N; Bergamo F; Rofi E; Barbara C; Falcone A; Santini D
JAMA Oncol; 2019 Mar; 5(3):343-350. PubMed ID: 30476968
[TBL] [Abstract][Full Text] [Related]
6. Validation of the Colon Life nomogram in patients with refractory metastatic colorectal cancer enrolled in the RECOURSE trial.
Pietrantonio F; Fucà G; Manca P; Pagani F; Raimondi A; Prisciandaro M; Randon G; Corti F; de Braud F; Cremolini C; Miceli R
Tumori; 2021 Aug; 107(4):353-359. PubMed ID: 33021466
[TBL] [Abstract][Full Text] [Related]
7. Nomogram predicted disease free survival for colorectal liver metastasis patients with preoperative chemotherapy followed by hepatic resection.
Liu W; Wang K; Han Y; Liang JY; Li YH; Xing BC
Eur J Surg Oncol; 2019 Nov; 45(11):2070-2077. PubMed ID: 31279595
[TBL] [Abstract][Full Text] [Related]
8. Treatment Patterns and Outcomes in Patients with KRAS Wild-Type Metastatic Colorectal Cancer Treated in First Line with Bevacizumab- or Cetuximab-Containing Regimens.
Houts AC; Ogale S; Sommer N; Satram-Hoang S; Walker MS
J Gastrointest Cancer; 2019 Mar; 50(1):69-77. PubMed ID: 29168112
[TBL] [Abstract][Full Text] [Related]
9. PTEN expression and KRAS mutations on primary tumors and metastases in the prediction of benefit from cetuximab plus irinotecan for patients with metastatic colorectal cancer.
Loupakis F; Pollina L; Stasi I; Ruzzo A; Scartozzi M; Santini D; Masi G; Graziano F; Cremolini C; Rulli E; Canestrari E; Funel N; Schiavon G; Petrini I; Magnani M; Tonini G; Campani D; Floriani I; Cascinu S; Falcone A
J Clin Oncol; 2009 Jun; 27(16):2622-9. PubMed ID: 19398573
[TBL] [Abstract][Full Text] [Related]
10. [Establishment of a prognostic nomogram to predict long-term survival in non-metastatic colorectal cancer patients].
Wang X; Chi P; Lin H; Lu X; Huang Y; Xu Z; Huang S; Sun Y; Ye D
Zhonghua Wei Chang Wai Ke Za Zhi; 2017 Jun; 20(6):654-659. PubMed ID: 28643310
[TBL] [Abstract][Full Text] [Related]
11. PREMIUM: A French prospective multicenter observational study of factors impacting on efficacy and compliance to cetuximab treatment in first-line KRAS wild-type metastatic colorectal cancer.
Mineur L; François E; Plassot C; Phelip JM; Miglianico L; Dourthe LM; Bonichon N; Moreau L; Guimbaud R; Smith D; Achille E; Hervé R; Bons JM; Remy S; Faroux R; Villing AL; Mahamat A; Rabbia I; Soulié P; Baumgaertner I; Mathé N; Vazquez L; Boustany R
PLoS One; 2020; 15(12):e0243997. PubMed ID: 33347495
[TBL] [Abstract][Full Text] [Related]
12. [Establishment of a nomogram predicting risk factors of postoperative perineal wound complications after abdominoperineal resection for rectal cancer].
Lu SQ; Chang XF; Yang XD; Yu DC; Huang QG; Wang F
Zhonghua Wei Chang Wai Ke Za Zhi; 2019 Apr; 22(4):357-363. PubMed ID: 31054550
[No Abstract] [Full Text] [Related]
13. Prognostic Impact of Primary Tumor Location on Clinical Outcomes of Metastatic Colorectal Cancer Treated With Cetuximab Plus Oxaliplatin-Based Chemotherapy: A Subgroup Analysis of the JACCRO CC-05/06 Trials.
Sunakawa Y; Ichikawa W; Tsuji A; Denda T; Segawa Y; Negoro Y; Shimada K; Kochi M; Nakamura M; Kotaka M; Tanioka H; Takagane A; Tani S; Yamaguchi T; Watanabe T; Takeuchi M; Fujii M; Nakajima T
Clin Colorectal Cancer; 2017 Sep; 16(3):e171-e180. PubMed ID: 27856123
[TBL] [Abstract][Full Text] [Related]
14. Skin Disorders and Primary Tumor Location as Prognostic Factors in Patients with Metastatic Colorectal Cancer Treated with Cetuximab and Chemotherapy.
Takada S; Sagawa T; Fujikawa K; Tahatsu K; Fukai Y; Hashishita H; Takahashi Y; Endo M
Asian Pac J Cancer Prev; 2018 Aug; 19(8):2325-2330. PubMed ID: 30141310
[TBL] [Abstract][Full Text] [Related]
15. Association of Primary Tumor Site With Mortality in Patients Receiving Bevacizumab and Cetuximab for Metastatic Colorectal Cancer.
Aljehani MA; Morgan JW; Guthrie LA; Jabo B; Ramadan M; Bahjri K; Lum SS; Selleck M; Reeves ME; Garberoglio C; Senthil M
JAMA Surg; 2018 Jan; 153(1):60-67. PubMed ID: 28975237
[TBL] [Abstract][Full Text] [Related]
16. Clinical outcomes and prognostic factors in recurrent and/or metastatic head and neck cancer patients treated with chemotherapy plus cetuximab as first-line therapy in a real-world setting.
Depenni R; Cossu Rocca M; Ferrari D; Azzarello G; Baldessari C; Alù M; Nolé F; Codecà C; Boscolo G; Piccininni M; Cavalieri S; Bossi P
Eur J Cancer; 2019 Jul; 115():4-12. PubMed ID: 31082692
[TBL] [Abstract][Full Text] [Related]
17. Effect of First-Line Chemotherapy Combined With Cetuximab or Bevacizumab on Overall Survival in Patients With KRAS Wild-Type Advanced or Metastatic Colorectal Cancer: A Randomized Clinical Trial.
Venook AP; Niedzwiecki D; Lenz HJ; Innocenti F; Fruth B; Meyerhardt JA; Schrag D; Greene C; O'Neil BH; Atkins JN; Berry S; Polite BN; O'Reilly EM; Goldberg RM; Hochster HS; Schilsky RL; Bertagnolli MM; El-Khoueiry AB; Watson P; Benson AB; Mulkerin DL; Mayer RJ; Blanke C
JAMA; 2017 Jun; 317(23):2392-2401. PubMed ID: 28632865
[TBL] [Abstract][Full Text] [Related]
18. Use of early tumor shrinkage to predict long-term outcome in metastatic colorectal cancer treated with cetuximab.
Piessevaux H; Buyse M; Schlichting M; Van Cutsem E; Bokemeyer C; Heeger S; Tejpar S
J Clin Oncol; 2013 Oct; 31(30):3764-75. PubMed ID: 24043732
[TBL] [Abstract][Full Text] [Related]
19. Establishment of Prognostic Nomograms for Predicting the Survival of HR-Positive, HER2-Negative Metastatic Breast Cancer Patients Treated with Everolimus.
Duan F; Song C; Ma Y; Jiang K; Xu F; Bi X; Huang J; Hong R; Huang Z; Lu Q; Yuan Z; Wang S; Xia W
Drug Des Devel Ther; 2021; 15():3463-3473. PubMed ID: 34408400
[TBL] [Abstract][Full Text] [Related]
20. Prognostic nomogram for previously untreated patients with esophageal squamous cell carcinoma after esophagectomy followed by adjuvant chemotherapy.
Duan J; Deng T; Ying G; Huang D; Zhang H; Zhou L; Bai M; Li H; Yang H; Qu Y; Wang X; Ba Y
Jpn J Clin Oncol; 2016 Apr; 46(4):336-43. PubMed ID: 26819278
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
